1020 ET - Tuesday's 27% selloff in Sarepta Therapeutics after the death of a patient who received its Elevidys gene therapy makes for a compelling buying opportunity, according to Mizuho. In a note, Mizuho's Uy Ear says Sarepta's current stock price captures little value for Elevidys, as the value of Sarepta's exon-skipping for Duchenne Muscular Dystrophy and limb-girdle muscular dystrophy businesses add up to about $70 a share. Mizuho, with an outperform rating and $190 price target on Sarepta, says Sarepta management is standing by its 2025 guidance, and the analysts still see the Elevidys benefit/risk profile as positive. Sarepta up 6.3% to $78.09. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 19, 2025 10:20 ET (14:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。